Clinical trials exist to find improved treatments for cancer patients and utilize the most recent innovations. Mesothelioma patients who feel that current treatments will not meet their needs sometimes consider clinical trials as a realistic path to follow.
and select 'Find A Clinical Trial' and then select "mesothelioma" as the 'Type of Cancer'.
|
Phase
|
IDs
|
| ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen |
III
|
ALFACELL-P30-302
NCT00003034, NCI-V97-1273
|
| Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma |
III
|
CRC-BOC-L52
EU-20033, NCT00006231
|
| Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma |
III
|
BTS-MRC-MS01
EU-20349, ISRCTN54469112, NCT00075699
|
| Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer |
III
|
FCCC-FCRB-04-002-P
NCT00372840
|
| Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma |
II
|
BC-MA-2
NCT00003508
|
| Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer |
II
|
SVMC-ONC-222
NCT00002475, NCI-V91-0075
|
| Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma |
II
|
RPCI-RP-9812
NCT00054002
|
| Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma |
II
|
ECOG-E1B03
NCT00101283, NCCTG-E1B03
|
| Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence |
II
|
SP-14-0038
NCT00123773
|
| Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
II
|
EORTC-08031
EudraCT-2004-004273-28, NCT00227630
|
| AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery |
II
|
SWOG-S0509
NCT00243074
|
| Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma |
II
|
03-369
NCT00137826
|
| Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma |
II
|
8848
NCT00192010, H3E-IT-S079
|
| AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery |
II
|
UCCRC-14203B
NCT00309946, NCI-7103
|
| A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence |
II
|
SP-14-0039
NCT00271648
|
| Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma |
II
|
AVF3442S
NCT00295503
|
| Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma |
II
|
SWS-SAKK-17/04
EU-20615, EUDRACT-2006-000445-19, LILLY-SAKK-17/04, NCT00334594
|
| Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma |
II
|
CASE-CCF-IRB-5179
CASE-CCF-0755, NCT00354393
|
| PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery |
II
|
CCC-PHII-67
NCT00365053, NCI-7255
|
| Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma |
II
|
CAN-NCIC-IND.183
NCT00392444
|
| Combination Chemotherapy in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases |
I
|
NCI-02-C-0205J
NCT00037817, NCI-5270
|
| Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies |
I
|
DFCI-03082
NCT00070239, NCI-6052
|
| FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer |
I
|
NCI-05-C-0010
NCT00094978, NCI-5987
|
| Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors |
I
|
2005_006
NCT00106626
|
| Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors |
I
|
CA225-101
NCT00207077
|
| Gene Therapy for Pleural Malignancies |
I
|
803776
NCT00299962, UPCC 03505
|
| Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) |
I
|
CS1008-A-U101
NCT00320827
|
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer |
I
|
MORAb-009-001
NCT00325494
|
| A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors |
I
|
CA187-002
NCT00329004
|
| A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer |
I
|
CA165-030
NCT00332748
|
| Monoclonal Antibody MORAb-009 in Treating Patients With Recurrent Advanced Tumors That Express Mesothelin |
I
|
NCI-06-C-0196
MORAb-009-001, NCI-P6942, NCT00325494
|
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma |
I
|
MSKCC-06085
NCT00398138
|
| EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer |
|
UPCC-05901
NCI-4110, UPCC-IRB-702341, NCT00028782
|
| Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery |
|
ICR-CTSU-MARS
EU-20532, NCT00253409
|
| Biobank Sarcoma: Storing Blood for Analysis of DNA and Protein of Patients With Sarcoma |
|
P04.0954L
NCT00181480
|
| Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers |
|
Asbestos Screening Study
NCT00188890
|
| Multiple Biomarkers in Undiagnosed Pleural Effusion |
|
FDI-02 Pleural Effusion Study
NCT00316134
|
